Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for...

NVS : 115.97 (+0.23%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE.This late-breaking data from this four-year post-hoc analysis was presented at the European...

NVS : 115.97 (+0.23%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
BAYRY : 7.7900 (+2.23%)
Lilly Gets FDA Approval for Eczema Drug Ebglyss

Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved...

NVS : 115.97 (+0.23%)
BIIB : 197.59 (-0.31%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab).The SC formulation was approved under the brand name Tecentriq...

NVS : 115.97 (+0.23%)
RHHBY : 39.6100 (+0.71%)
LLY : 904.97 (-0.13%)
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the industry...

NVS : 115.97 (+0.23%)
RHHBY : 39.6100 (+0.71%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous urticaria (CSU)...

REGN : 1,138.81 (-0.69%)
SNY : 57.47 (+0.98%)
NVS : 115.97 (+0.23%)
RHHBY : 39.6100 (+0.71%)
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...

MRK : 118.64 (+0.30%)
NVS : 115.97 (+0.23%)
KTRA : 0.1750 (-8.42%)
RKV.VN : 0.085 (-5.56%)
RHHBY : 39.6100 (+0.71%)
XBIT : 7.50 (+1.49%)
BMRN : 71.14 (+0.84%)
AZN : 78.58 (+0.06%)
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg

Bayer BAYRY announced positive results from the expansion part of the ongoing early to mid-stage study on pipeline candidate BAY 2927088.BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI)...

REGN : 1,138.81 (-0.69%)
NVS : 115.97 (+0.23%)
LLY : 904.97 (-0.13%)
BAYRY : 7.7900 (+2.23%)
Chart of the Day: Novartis - Take Another Look

The Chart of the Day belongs to the Swiss pharmaceutical company Novartis (NVS) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals,...

NVS : 115.97 (+0.23%)
Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy

/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) applauds the work done by Muscular Dystrophy Canada and the provinces to ensure that every newborn in...

NVS : 115.97 (+0.23%)

Barchart Exclusives

Stocks Soar Before the Open as Fed’s Big Rate Cut Boosts Sentiment, U.S. Economic Data and FedEx Earnings on Tap
September S&P 500 E-Mini futures (ESU24) are up +1.48%, and September Nasdaq 100 E-Mini futures (NQU24) are up +2.03% this morning on expectations the Federal Reserve’s half-percentage-point rate cut will steer the U.S. economy toward a “soft landing,” while investors awaited a new round of U.S. economic data and an earnings report from delivery services giant FedEx. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar